Home › Companies › Fidelix

Fidelix

피델릭스 · 032580 · KOSDAQ
Filings, last 12 months
33
Supply contracts
6
Insider reports
2
Share & bond issues
0

At a glance

Fidelix filed 33 disclosures in the last 12 months, including 6 contract, 2 insider and 1 5% holder. The most recent key filing was on Oct 13: Worth 11.3% of last year's revenue, over about 1 month.

Revenue for 2025 was ₩53.6B, up 19.6% on 2024. It made an operating loss of ₩2.1B. Debt was 28% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩54.9B and operating profit of ₩13.9B.

The 2025 annual report lists 63 employees with an average tenure of 7.5 years and average pay of ₩78.2M, #411 of 1,829 listed companies by average pay. Its 5 directors and auditors were paid ₩91.7M each on average. It paid no cash dividend for 2025. 동심반도체주식유한공사 (Dosilicon Co., Ltd.) and related parties held 30.50% at year end.

From the 2025 annual report

Employees
63
Average pay
₩78.2M
Average tenure
7.5 yrs
Avg. director pay
₩91.7M

Staff: 63 (56 men, 7 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩5.1B. Directors and auditors: 5, paid ₩458.7M in total.

No cash dividend was paid for 2025.

Largest shareholder

동심반도체주식유한공사 (Dosilicon Co., Ltd.) holds 30.20%; with 1 related party the group holds 30.50% of common shares at year end.

Auditor: 대성회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

5 new supply contracts worth 103% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary

2023
Revenue ₩52.8B
Op. profit ₩710.1M
Debt/equity 15%
2024
Revenue ₩44.8B
Op. profit -₩4.5B
Debt/equity 19%
2025
Revenue ₩53.6B
Op. profit -₩2.1B
Debt/equity 28%
2026 H1
Revenue ₩54.9B
Op. profit ₩13.9B
Debt/equity 41%
RevenueOperating profitOperating lossConsolidated where available · from periodic reports

Key filings

Other filings

Links open the original filing on DART, in Korean.